Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Stem Cells in Achilles Tendinopathy
NCT02064062Phase 2Unknown
- Sponsor
- University College London
- Start
- Jan 2015
- Primary completion
- Dec 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous mesenchymal stem cells in Achilles tendinopathy, sponsored by University College London. Primary endpoint: Incidence rate of Serious Adverse Reaction at 6 months. Status: unknown.
02
Drugs
autologous mesenchymal stem cells
03
Conditions
Achilles tendinopathy
Beyond the preview
Go deeper on NCT02064062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02064062.